AMS reports 29% revenue growth for 2025, raises dividend by 10%

Revenue grew 29% in FY2025 with adjusted EBITDA up 24% and adjusted EPS rising 12% to £0.12 (statutory EPS £0.05); adjusted pretax profit was £33.9m versus statutory pretax £17.8m. The board proposed a 10% full-year dividend increase. 2026 guidance calls for revenue of £245.3m and adjusted EBITDA of £55.2m, driven by full-year contribution from Peters Surgical and Syntacoll acquisitions and continued Surgical strength; Woundcare returned to growth post-restructuring. Management expects multiple product approvals from 2026 onward, supporting medium-term growth.

Analysis

The company's recent string of acquisitions and product approvals materially repositions it from a niche woundcare player toward a higher-margin surgical adhesives/sutures vendor. That creates two second-order effects: distributors and large hospital procurement networks will try to extract concessions as the combined product set overlaps existing contracts, and the firm gains optionality to cross-sell into operating-room consumable bundles where pricing power is stickier and ASPs are higher. Expect margin expansion driven more by mix shift and direct-supply agreements than by pure organic volume growth — a sustainable driver if integration stays on schedule.

Key execution risks live in the 6–24 month window: regulatory approvals and CE/FDA timelines, integration costs that can depress near-term margins, and raw-material concentration (collagen/adhesive chemistries) that can swing COGS if a supplier hiccups or if input prices spike. Currency exposure and regional reimbursement moves in the US/Asia markets can amplify or negate reported growth — monitor quarterly gross-margin cadence and distributor payment terms as early read-throughs. A single large tender loss or a delayed approval could erase expected upside within a quarter.

The market has likely underpriced the optionality of bundled-surgical sales but may be over-enthusiastic on near-term margin permanence; that sets up asymmetric payoff for event-driven positions around approval milestones and integration updates. Watch for upcoming regulatory decision windows, large hospital procurement cycles, and any announced vertical-sourcing moves — these are 3–12 month catalysts that will re-rate the equity more than headline top-line beats alone.

Key Decisions for Investors

• Long AMS (small position, 1–2% net exposure) into any market pullback of 5–10%; 12-month target +30%, hard stop -30% — thesis: mix-driven margin expansion and cross-sell optionality materialize within 12 months.
• Buy a defined-risk options structure: purchase 12–18 month AMS call and hedge by selling a nearer-term call (call spread) to turn cost into a 2:1 upside skew; target 3x+ payoff if two 2026 regulatory approvals clear.
• Event pair: long AMS / short SYK (equal $ notional) for a 6–12 month trade to isolate small-cap surgical-adhesive execution versus large-cap equipment exposure; reduces macro/healthcare beta while expressing surgical consumable upside.
• Hedge for downside risk: purchase a 6–9 month AMS put spread (25–40% OTM) ahead of key approval or integration milestones to cap tail risk from regulatory delays or large tender losses.